BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

Stock Information for BriaCell Therapeutics Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BriaCell Therapeutics Corp.

BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
BriaCell Provides Update to its Board of Directors
BriaCell Announces First Patient Dosed with Bria-OTS(TM) in Metastatic Breast Cancer Study
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 - 13
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
BriaCell Therapeutics Announces Closing of $5 Million Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.